AFT hits US approval target, triggers cash

AFT hits US approval target, triggers cash
Managing director Hartley Atkinson said Maxigesic was an effective alternative for the US$700 million of IV paracetamol sold each year. (Photo: supplied).
Dan Brunskill
The United States medical regulator has accepted an application for AFT Pharmaceuticals’ patented pain relief medicine, which if approved would open up a more than US$300 million market.The US Food and Drug Administration has formally received the application for Maxigesic IV, an intravenous form of AFT’s painkiller, which was filed in August this year.Filing with the FDA triggers milestone payments worth US$3.6m under a licensing deal with US partner Hikma Pharmaceuticals. This will be recognised in the first half of the current fi...

More Markets

Vector agrees to sell LPG assets for $150m
Markets

Vector agrees to sell LPG assets for $150m

The deal is subject to regulatory approvals and commercial conditions.

Rebecca Howard 26 Jul 2024
ASX: Australian shares slide to a two-week low as tech drags
Markets

ASX: Australian shares slide to a two-week low as tech drags

Every sector of the Australian share market has lost ground.

AAP 26 Jul 2024
NZ sharemarket down 0.38%
Markets Market close

NZ sharemarket down 0.38%

The S&P/NZX 50 Index closed at the day’s low of 12,349.47, down 46.79 points or 0.38%.

Graham Skellern 26 Jul 2024
The Warehouse’s plight in five charts
Retail Charts

The Warehouse’s plight in five charts

The private equity bid shows the company’s future is still anyone’s guess.

Gregor Thompson 26 Jul 2024